Laurens F. Tops

Laurens F. Tops

Auto-generated profile, based on publicly available information

Laurens F. Tops

Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2023 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
DSDiyar Saeed
Diyar Saeed
DFDavid Feldman
David Feldman
ABAly El Banayosy
Aly El Banayosy
EBEmma Birks
Emma Birks
EBElizabeth Blume
Elizabeth Blume
DDDavid D'ALessandro
David D'ALessandro

21 May 2019 in European Heart Journal
Verified
Journal Article
Closed access
APAnnelieke H J Petrus
Annelieke H J Petrus
ODOlaf M Dekkers
Olaf M Dekkers
LTLaurens F Tops
Laurens F Tops
ETEva Timmer
Eva Timmer
RKRobert J.M. Klautz
Robert J.M. Klautz
JBJerry Braun
Jerry Braun
Aims: Recurrent mitral regurgitation (MR) has been reported after mitral valve repair for functional MR. However, the impact of recurrent MR on long-term survival remains poorly defined. In the present study, mortality-adjusted recurrent MR rates, the clinical impact of recurrent MR and its determinants were studied in patients after mitral valve repair with revascularization for functional MR in the setting of ischaemic heart disease. Methods and results: Long-term clinical and echocardiographic outcome was evaluated in 261 consecutive patients after restrictive mitral annuloplasty and revascularization for moderate to severe functional MR, between 2000 and 2014. The cumulative incidence of recurrent MR ≥ Grade 2, assessed by competing risk analysis, was 9.6 ± 1.8% at 1-year, 20.3 ± 2.5% at 5-year, and 27.6 ± 2.9% at 10-year follow-up. Cumulative survival was 85.8% [95% confidence interval (CI) 81.0–90.0] at 1-year, 67.3% (95% CI 61.1–72.6%) at 5-year, and 46.1% (95% CI 39.4–52.6%) at 10-year follow-up. Age, preoperative New York Heart Association Class III or IV, a history of renal failure, and recurrence of MR expressed as a time-dependent variable [HR 3.28 (1.87–5.75), P < 0.001], were independently associated with an increased mortality risk. Female gender, a history of ST-elevation myocardial infarction, a preoperative QRS duration ≥120 ms, a higher preoperative MR grade, and a higher indexed left ventricular end-systolic volume were independently associated with an increased likelihood of recurrent MR. Conclusion: Mitral valve repair for functional ischaemic MR resulted in a low incidence of recurrent MR with favourable clinical outcome up to 10 years after surgery. Presence of recurrent MR at any moment after surgery proved to be independently associated with an increased risk for mortality.

12 February 2022 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
PDF file
TBTheo M M H de By
Theo M M H de By
FSFelix Schoenrath
Felix Schoenrath
KVKevin M Veen
Kevin M Veen
PMPaul Mohacsi
Paul Mohacsi
JSJulia Stein
Julia Stein
BMBart Meyns
Bart Meyns
In the third report of the European Registry for Patients with Mechanical Circulatory Support of the European Association for Cardio-Thoracic Surgery, outcomes of patients receiving mechanical circulatory support are reviewed in relation to implant era. Procedures in adult patients (January 2011–June 2020) were included. Patients from centres with <60% follow-ups completed were excluded. Outcomes were stratified into 3 eras (2011–2013, 2014–2017 and 2018–2020). Adverse event rates (AERs) were calculated and stratified into early phase (3 months). Risk factors for death were explored using univariable Cox regression with a stepwise time-varying hazard ratio (3 months). In total, 4834 procedures in 4486 individual patients (72 hospitals) were included, with a median follow-up of 1.1 (interquartile range: 0.3–2.6) years. The annual number of implants (range: 346–600) did not significantly change (P = 0.41). Both Interagency Registry for Mechanically Assisted Circulatory Support class (classes 4–7: 23, 25 and 33%; P < 0.001) and in-hospital deaths (18.5, 17.2 and 11.2; P < 0.001) decreased significantly between eras. Overall, mortality, transplants and the probability of weaning were 55, 25 and 2% at 5 years after the implant, respectively. Major infections were mainly noted early after the implant occurred (AER<3 months: 1.44 vs AER>3 months: 0.45). Bilirubin and creatinine levels were significant risk factors in the early phase but not in the late phase after the implant. In its 10 years of existence, EUROMACS has become a point of reference enabling benchmarking and outcome monitoring. Patient characteristics and outcomes changed between implant eras. In addition, both occurrence of outcomes and risk factor weights are time dependent.

14 June 2024 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
IHIan B. Hollis
Ian B. Hollis
DJDouglas L. Jennings
Douglas L. Jennings
SKSelim Krim
Selim Krim
VTVan-Khue Ton
Van-Khue Ton
ADAnique Ducharme
Anique Ducharme
RRRavi K. Ratnagiri
Ravi K. Ratnagiri

28 January 2025 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Open access
KVKevin M Veen
Kevin M Veen
MAMazen Ahmed
Mazen Ahmed
CSChristoffer Stark
Christoffer Stark
LBLuca Botta
Luca Botta
KAKyriakos Anastasiadis
Kyriakos Anastasiadis
FSFelix Schoenrath
Felix Schoenrath
OBJECTIVES: This 4th report aimed to provide insights into patient characteristics, outcomes and standardized outcome ratios of patients implanted with durable Mechanical Circulatory Support across participating centres in the European Registry for Patients with Mechanical Circulatory Support (EUROMACS) registry. METHODS: All registered patients receiving durable mechanical circulatory support up to August 2024 were included. The expected number of events was predicted using penalized logistic regression. Standardized outcome ratios (Observed/Expected events) were presented in plots to assess 30-day and 1-year mortality, ischaemic stroke and major bleeding outcomes. Expected events were estimated using penalized logistic regression using demographics and comorbidities as predictors. Centres with <90% follow-up completeness were excluded from standardized outcome ratio assessment. RESULTS: Analysis included 6962 implants in 6408 patients (457 patients underwent repeated implants) registered in EUROMACS from 17 countries (32 centres) (median age: 58 years, 83% males, 17% Interagency Registry for Mechanically Assisted Circulatory Support class 1). Thirty-day mortality, major bleeding and ischaemic stroke probabilities were 9.6, 12.6% and 2.1%, respectively. Standardized mortality ratios showed variability between centres, ranging from 0 (95% CI 0–0) to 1.4 (95% CI 1.2–1.7). Higher standardized bleeding outcome ratios correlated with higher standardized ischaemic stroke ratio’s (Spearman r: 0.56, P = 0.008). CONCLUSIONS: Most included centres perform as expected given the demographics and comorbidities of patients. A positive correlation was found between standardized bleeding and ischaemic stroke ratios, reflecting the need of continuously monitoring of adverse events by quality improvement programs.

14 October 2025 in European Journal of Heart Failure
Verified
Journal Article
Closed access
LTLaurens F. Tops
Laurens F. Tops
AAAlberto Aimo
Alberto Aimo
SAStamatis Adamopoulos
Stamatis Adamopoulos
MBMichael Bonios
Michael Bonios
AÇAhmet Çelik
Ahmet Çelik
TGTuvia Ben Gal
Tuvia Ben Gal
This clinical consensus statement outlines the vital role of multimodality imaging in managing patients with advanced heart failure (HF), particularly those receiving mechanical circulatory support (MCS) and heart transplantation (HT). For both temporary and durable MCS, multimodality imaging, primarily echocardiography, is crucial for selecting candidates, ensuring proper device placement, and monitoring in the post-implantation period. Preoperatively, it helps to identify HF phenotypes, assess ventricular functions, detect intracardiac thrombi, and evaluate valvular conditions. Key measurements include ventricular size, ejection fraction, and cardiac output. Intraoperative imaging ensures optimal device placement and complication detection. Post-implantation echocardiography gives an impression of the interplay between heart and MCS, detects early complications, and evaluates ventricular unloading and right ventricular function. Serial imaging evaluations are essential for the management of the patient and the device and for diagnosing and treatment of complications. In temporary MCS, imaging is vital in the weaning process. Imaging is crucial across various post-transplant phases, from early postoperative monitoring to long-term follow-up. Echocardiography is the first-line technique. Cardiovascular magnetic resonance provides detailed evaluation of cardiac structure and function, offering insights into fibrosis, oedema, and myocardial perfusion. Coronary computed tomography angiography and positron emission tomography are possible alternatives for assessing coronary allograft vasculopathy. Overall, multimodality imaging is pivotal for comprehensive management of patients potentially eligible to or undergoing MCS or HT, enhancing diagnostic accuracy and guiding therapeutic decisions.